Hangzhou, China - October 20, 2023 - Hangzhou Sumgen Biotech Co., Ltd. (hereinafter referred to as "Sumgen Biotech") announced that it has received regulatory approval from the National Medical Products Administration (NMPA) to commence clinical trials for its proprietary novel ADC drug candidate SG2918 for injection, for the treatment of advanced malignant tumors. SG2918 is the first ADC candidate from Sumgen Biotech’s pipeline to be approved for clinical use, and it is first-in-class ADC approved for clinical trials.
Copyright Rm. 301, F3, Building C, Block 2, No. 688, Bin'an Road, Changhe Zhejiang ICP Filing No. 18039044
